The future of prostate cancer screening in the European Union: PRAISE-U project.

INTRODUCTION

Prostate cancer (PCa) remains one of the leading public health challenges among European men. Despite technological advances, its early detection continues to be controversial due to the risk of overdiagnosis and the limited adoption of organized screening programs.

MATERIALS AND

METHODS

A review was conducted of scientific literature, institutional reports, and technical documentation from the PRAISE-U project. We describe the key components of its design, implementation and lessons learned at two pilot sites in Spain (Galicia and Manresa), with a focus on personalized strategies and operational efficiency.

RESULTS

Based on the European Union recommendation of 2022, the PRAISE-U project promotes a risk-based screening program that incorporates prostate-specific antigen (PSA), magnetic resonance imaging (MRI) and risk calculators (RC). Galicia and Manresa have developed screening circuits adapted to their health systems. Galicia has managed to invite 7000 of the 12,000 target men in less than a year, integrating digital tools and direct contact strategies. Manresa, from primary care, has developed a coordinated approach focused on accessibility and traceability. Both models prioritize equity, adherence and minimization of overtreatment.

CONCLUSIONS

The PRAISE-U project offers an innovative and adaptable framework for PCa screening in Europe. The Spanish experience demonstrates that it is possible to implement effective and risk-focused early detection programs, provided that there is sound planning, technological tools and a collaborative approach between levels of care.